Identification of Lead Inhibitors for 3CLpro of SARS-CoV-2 Target Using Machine Learning Based Virtual Screening, ADMET Analysis, Molecular Docking and Molecular Dynamics Simulations

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2024 Sep 19

PMID 39297030

Authors

Sandeep Poudel Chhetri

Vishal Singh Bhandari

Rajesh Maharjan

Tika Ram Lamichhane

Affiliations

Soon will be listed here.

Abstract

The SARS-CoV-2 3CLpro is a critical target for COVID-19 therapeutics due to its role in viral replication. We employed a screening pipeline to identify novel inhibitors by combining machine learning classification with similarity checks of approved medications. A voting classifier, integrating three machine learning classifiers, was used to filter a large database (∼10 million compounds) for potential inhibitors. This ensemble-based machine learning technique enhances overall performance and robustness compared to individual classifiers. From the screening, three compounds M1, M2 and M3 were selected for further analysis. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis compared these candidates to nirmatrelvir and azvudine. Molecular docking followed by 200 ns MD simulations showed that only M1 (6-[2,4-bis(dimethylamino)-6,8-dihydro-5-pyrido[3,4-d]pyrimidine-7-carbonyl]-1-pyrimidine-2,4-dione) remained stable. For azvudine and M1, the estimated median lethal doses are 1000 and 550 mg kg, respectively, with maximum tolerated doses of 0.289 and 0.614 log mg per kg per day. The predicted inhibitory activity of M1 is 7.35, similar to that of nirmatrelvir. The binding free energy based on Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) of M1 is -18.86 ± 4.38 kcal mol, indicating strong binding interactions. These findings suggest that M1 merits further investigation as a potential SARS-CoV-2 treatment.

References

Salimi A, Lim J, Jang J, Lee J . The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors. Sci Rep. 2022; 12(1):18825. PMC: 9637137. DOI: 10.1038/s41598-022-22992-6. View

Li G, Hilgenfeld R, Whitley R, De Clercq E . Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023; 22(6):449-475. PMC: 10113999. DOI: 10.1038/s41573-023-00672-y. View

Pires D, Blundell T, Ascher D . pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9):4066-72. PMC: 4434528. DOI: 10.1021/acs.jmedchem.5b00104. View

Zhong F, Xing J, Li X, Liu X, Fu Z, Xiong Z . Artificial intelligence in drug design. Sci China Life Sci. 2018; 61(10):1191-1204. DOI: 10.1007/s11427-018-9342-2. View

Khanal M, Acharya A, Maharjan R, Gyawali K, Adhikari R, Das Mulmi D . Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM/GBSA calculations, DFT studies, and pharmacokinetic analysis. PLoS One. 2024; 19(7):e0307501. PMC: 11262678. DOI: 10.1371/journal.pone.0307501. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

Anand K, Ziebuhr J, Wadhwani P, Mesters J, Hilgenfeld R . Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003; 300(5626):1763-7. DOI: 10.1126/science.1085658. View

Mendez D, Gaulton A, Bento A, Chambers J, de Veij M, Felix E . ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2018; 47(D1):D930-D940. PMC: 6323927. DOI: 10.1093/nar/gky1075. View

Delaney J . ESOL: estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci. 2004; 44(3):1000-5. DOI: 10.1021/ci034243x. View

10.

Touw W, Baakman C, Black J, Te Beek T, Krieger E, Joosten R . A series of PDB-related databanks for everyday needs. Nucleic Acids Res. 2014; 43(Database issue):D364-8. PMC: 4383885. DOI: 10.1093/nar/gku1028. View

11.

Rose P, Prlic A, Altunkaya A, Bi C, Bradley A, Christie C . The RCSB protein data bank: integrative view of protein, gene and 3D structural information. Nucleic Acids Res. 2016; 45(D1):D271-D281. PMC: 5210513. DOI: 10.1093/nar/gkw1000. View

12.

Riniker S, Landrum G . Similarity maps - a visualization strategy for molecular fingerprints and machine-learning methods. J Cheminform. 2013; 5(1):43. PMC: 3852750. DOI: 10.1186/1758-2946-5-43. View

13.

Chicco D, Warrens M, Jurman G . The coefficient of determination R-squared is more informative than SMAPE, MAE, MAPE, MSE and RMSE in regression analysis evaluation. PeerJ Comput Sci. 2021; 7:e623. PMC: 8279135. DOI: 10.7717/peerj-cs.623. View

14.

Valdes-Tresanco M, Valdes-Tresanco M, Valiente P, Moreno E . gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J Chem Theory Comput. 2021; 17(10):6281-6291. DOI: 10.1021/acs.jctc.1c00645. View

15.

Bojarska J, Remko M, Breza M, Madura I, Kaczmarek K, Zabrocki J . A Supramolecular Approach to Structure-Based Design with A Focus on Synthons Hierarchy in Ornithine-Derived Ligands: Review, Synthesis, Experimental and in Silico Studies. Molecules. 2020; 25(5). PMC: 7179192. DOI: 10.3390/molecules25051135. View

16.

Lamichhane T, Ghimire M . Evaluation of SARS-CoV-2 main protease and inhibitor interactions using dihedral angle distributions and radial distribution function. Heliyon. 2021; 7(10):e08220. PMC: 8525048. DOI: 10.1016/j.heliyon.2021.e08220. View

17.

Agbowuro A, Huston W, Gamble A, Tyndall J . Proteases and protease inhibitors in infectious diseases. Med Res Rev. 2017; 38(4):1295-1331. DOI: 10.1002/med.21475. View

18.

Kola I, Landis J . Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004; 3(8):711-5. DOI: 10.1038/nrd1470. View

19.

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

20.

Silva R, Freitas H, Campos J, Kimani N, Silva C, Borges R . Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. Int J Mol Sci. 2021; 22(21). PMC: 8583940. DOI: 10.3390/ijms222111739. View